dsdsa

product

Factory source Anti-Cancer Paclitaxel - High Purity Ready Stock 61825-94-3 Oxaliplatin for Platinum Anticancer Drugs – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

With our leading technology at the same time as our spirit of innovation,mutual cooperation, benefits and growth, we're going to build a prosperous future together with your esteemed firm for Melatonine Powder, Ruxolitinib Phosphate, Yohimbine, Our business has already setup a professional, creative and responsible workforce to develop purchasers together with the multi-win principle.
Factory source Anti-Cancer Paclitaxel - High Purity Ready Stock 61825-94-3 Oxaliplatin for Platinum Anticancer Drugs – Yibai Detail:

Product name Oxaliplatin
Synonyms trans-L-Diaminocyclohexane oxalatoplatinum
CAS No. 61825-94-3
Appearance White to off white crystallization powder
Molecular Formula C8H12N2O4Pt
Molecular Weight 395.27
Usage Pharmaceutical Grade or Research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Oxaliplatin Cas: 61825-94-3

Items

Standard

Results

Appearance White or almost white crystalline powder White crystalline powder
Solubility Slightly soluble in water ,very slightly soluble in methanol, practically insoluble in anhydrous ethanol Complies
Identification   Spectrum of sample should consistent with spectrum of reference standard A.CompliesB.Complies
Apearance of solution The solution is clear and colourless Complies
Acidity Not more than 0.6ml of 0.01M NaOH is required to change the colour of the indicator to pink Complies
Specific optical rotation +74.5°~+78.0° +75.9°
Related substances ImpurityA:NMT0.10%ImpurityB: NMT0.10%

ImpurityC: NMT0.10%

Any other impurity:NMT0.10%

Total of other impurities: NMT0.10%

(include impurity C)                     

Total of impurities: NMT0.30%

ImpurityA: 0.04%  ImpurityB:0.01%ImpurityC: 0.001%

Any other impurities: 0.002%

Total of other impurities:

0.01%

Total of impurities: 0.03%

Impurity D NMT0.10% N.D
Silver NMT5.0ppm 0.08ppm
Loss on drying NMT0.5% 0.09%
Assay 98.0~102.0% (dried substance) 99.7%
Conclusion: The results show that the product complies with EP9.0

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Factory source Anti-Cancer Paclitaxel - High Purity Ready Stock  61825-94-3 Oxaliplatin for Platinum Anticancer Drugs – Yibai detail pictures

Factory source Anti-Cancer Paclitaxel - High Purity Ready Stock  61825-94-3 Oxaliplatin for Platinum Anticancer Drugs – Yibai detail pictures

Factory source Anti-Cancer Paclitaxel - High Purity Ready Stock  61825-94-3 Oxaliplatin for Platinum Anticancer Drugs – Yibai detail pictures


Related Product Guide:

Our products are broadly identified and trustworthy by people and may meet continually modifying financial and social requires of Factory source Anti-Cancer Paclitaxel - High Purity Ready Stock 61825-94-3 Oxaliplatin for Platinum Anticancer Drugs – Yibai , The product will supply to all over the world, such as: Iraq, Provence, Denver, Due to our dedication, our products are well known throughout the world and our export volume continuously grows every year. We will continue to strive for excellence by providing high quality products that will exceed the expectation of our customers.
  • After the signing of the contract, we received satisfactory goods in a short term, this is a commendable manufacturer.
    5 Stars By Kay from St. Petersburg - 2017.12.09 14:01
    The company has rich resources, advanced machinery, experienced workers and excellent services, hope you keep improving and perfecting your products and service, wish you better!
    5 Stars By Federico Michael Di Marco from Dubai - 2017.12.19 11:10
    Write your message here and send it to us